Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabrafenib + trametinib
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dabrafenib and trametinib are small molecule kinase inhibitors used in combination as a targeted therapy for cancers with BRAF V600 mutations. Dabrafenib is a selective inhibitor of the BRAF protein, which is part of the MAPK/ERK signaling pathway that promotes cell proliferation and survival. Trametinib inhibits MEK1 and MEK2, downstream kinases in the same pathway. By blocking both BRAF and MEK, this combination disrupts cancer cell growth more effectively than either agent alone. The combination is primarily indicated for melanoma (including adjuvant treatment after surgery), advanced non-small cell lung cancer (NSCLC), certain types of thyroid cancer, solid tumors with BRAF V600E mutation in adults and children 6 years or older, and glioma in children 1 year or older.
- Brand names
- Tafinlar + Mekinist
- Other names
- dabrafenib + trametinib
02
Targets
MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)BRAF V600EMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on dabrafenib + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabrafenib + trametinib.